Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) issued its quarterly earnings results on Thursday. The company reported ($0.09) EPS for the quarter, topping the consensus estimate of ($0.21) by $0.12, Zacks reports. The company had revenue of $0.03 million for the quarter, compared to the consensus estimate of $2.98 million.
Autolus Therapeutics Stock Up 0.6 %
AUTL stock traded up $0.01 during midday trading on Monday, reaching $1.71. The company had a trading volume of 1,072,844 shares, compared to its average volume of 1,380,174. The stock has a 50 day moving average price of $2.01 and a 200 day moving average price of $2.88. The firm has a market capitalization of $455.02 million, a PE ratio of -1.41 and a beta of 2.07. Autolus Therapeutics has a fifty-two week low of $1.56 and a fifty-two week high of $6.60.
Analyst Ratings Changes
Several brokerages have issued reports on AUTL. Wells Fargo & Company cut their price objective on Autolus Therapeutics from $8.00 to $6.00 and set an "overweight" rating on the stock in a research note on Friday. Needham & Company LLC reissued a "buy" rating and set a $10.00 price target on shares of Autolus Therapeutics in a research report on Monday, January 13th. Six analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus price target of $9.52.
Check Out Our Latest Analysis on Autolus Therapeutics
About Autolus Therapeutics
(
Get Free Report)
Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.
Recommended Stories
Before you consider Autolus Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Autolus Therapeutics wasn't on the list.
While Autolus Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
